Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LIPOmRNA

Financiado

Cerrado

ModeRN Approach to ocular disease treatment - Smart lipid-based nanoparticle sys...

ModeRN Approach to ocular disease treatment - Smart lipid-based nanoparticle systems for the delivery of mRNA to the ocular tissues Many severe ocular diseases lead to visual impairment and blindness in millions of patients worldwide, and the number is rapidly growing in aging populations. Most ocular diseases are still without drug treatment and the current t... ver más

31/07/2025

UNIVERSITY OF EAST...

200K€

Presupuesto del proyecto: 200K€

Líder del proyecto

ITASUOMEN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-24

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNIVERSITY OF EASTERN FINLAN...

199.69K€ | Lider

HELSINGIN YLIOPISTO

N.D. | Participante

UNIPD

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NANOIDROPS Nucleic acid nanoparticles for topical ophthalmic drug deliv... 168K€ Cerrado

NanoRet Nanocarriers Optimization for Periocular Drug Delivery to th... Cerrado

EEBB-I-12-05371 COMBINACION DE HIDROGELES BIOMIMETICOS Y NANOPARTICULAS COMO... 6K€ Cerrado

BES-2011-046381 COMBINACION DE HIDROGELES BIOMIMETICOS Y NANOPARTICULAS COMO... 41K€ Cerrado

DELIVER Release of engineered extracellular vesicles for delivery of... 2M€ Cerrado

DYE-LIGHT Pulsed Laser Light and Nano-encapsulated Ocular Dyes for Adv... 1M€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2023-03-24
Fecha Fin: 2025-07-31

Líder del proyecto

ITASUOMEN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 200K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many severe ocular diseases lead to visual impairment and blindness in millions of patients worldwide, and the number is rapidly growing in aging populations. Most ocular diseases are still without drug treatment and the current treatments are based on the use of small molecules and protein drugs. However, poor ocular absorption and rapid elimination restrict their development and use in ophthalmology. Technology for mRNA transfer into the cornea and retina and subsequent expression of encoded proteins may open widely applicable possibilities for the treatment of ocular diseases (e.g. various retinal degenerations, uveitis) as topical eye drops or intravitreal injections. However, clinical application of mRNAs is limited by their poor in vivo stability and low cellular entry. Therefore, efficient and safe delivery systems for ocular mRNA transfer are urgently needed. Our research program aims to develop lipid-based nanoparticle (LNP) systems that are specifically tailored for mRNA delivery into the corneal, conjunctival and retinal cells. The project will address the critical anatomical and physiological barriers of ocular mRNA delivery topically and intravitreally. Chemical structure and composition of LNPs will be carefully modified to optimize mRNA delivery across ocular barriers. Smart pH-sensitive LNPs with eye specific surface moieties will be used to target ocular cells and trigger mRNA release and cytosolic delivery. Moreover, eye drop formulations will be mucoadhesive, increasing precorneal residence time, whereas intravitreal injectables will be capable of permeating in the vitreous and inner limiting membrane into the retinal cells. The representative in vitro and ex vivo test models will be used to select the most promising LNPs for versatile animal experiments. Finally, in vivo pharmacokinetics and mRNA mediated anti-VEGF responses of the delivery systems will be investigated to understand their translational potential towards clinical use.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores